Back to top

GoodRx: Strengthening Fundamentals, GLP-1 Momentum Drive DCF Upgrade and Higher $5 Price Target Supporting Buy Rating

Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on GoodRx Holdings. The associated price target was raised to $5.00. Charles Rhy...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

GoodRx Holdings, Inc. (GDRX)